🔎 Trials Near Me

Utama › Kanser Prostat › Texas

Kajian klinikal Kanser Prostat di Texas

115 kajian untuk Kanser Prostat sedang mencari peserta di lokasi di Texas.

Bandar di Texas

Teks kajian rasmi (Bahasa Inggeris)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • New Experimental Therapeutics - NEXT Oncology, Austin
  • Texas Oncology, Bedford
  • UT Southwest Simmons Cancer Center, Dallas
  • dan 2 lagi
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 2 Okt 2026 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • Covenant Medical Center-Lakeside, Lubbock
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 2 Okt 2026 · NCT07200830

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), San Antonio
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06632977

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06172478

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  • MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 28 Sep 2026 · NCT06095089

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

  • Urology Austin, Austin
Mengambil peserta
Umur 18 ke atas · Lelaki · Dikemas kini 28 Sep 2026 · NCT06496256

DESTINY-PANTUMOUR04

  • Research Site, Dallas
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

  • The University of Texas M. D. Anderson Cancer Center, Houston
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT06759701

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

  • M D Anderson Cancer Center, Houston
Mengambil peserta
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT07377006

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  • Research Site, Houston
Mengambil pesertaFasa 1/2
Umur 18 hingga 130 · Lelaki · Dikemas kini 25 Sep 2026 · NCT07181161

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  • NEXT Oncology, Austin
  • MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT06800313

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • Texas Oncology - Central/South Texas ( Site 8003), Austin
  • Texas Oncology - DFW ( Site 8001), Dallas
  • Texas Oncology - Gulf Coast ( Site 8002), Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06136650

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  • University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
  • University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
  • University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 24 Sep 2026 · NCT07028853

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

  • START Dallas-Fort Worth, Fort Worth
  • NEXT Houston, Houston
  • NEXT Oncology, San Antonio
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 24 Sep 2026 · NCT07719361

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  • Texas Oncology, Dallas
  • Urology San Antonio, San Antonio
Mengambil pesertaFasa 2/3
Umur 18 hingga 100 · Lelaki · Dikemas kini 22 Sep 2026 · NCT06780670

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

  • Mary Crowley Cancer Research, Dallas
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 22 Sep 2026 · NCT07570979

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Texas Oncology - DFW (Sammons CC), Dallas
  • MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07114601

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • The Center for Cancer and Blood Disorders, Arlington
  • University of Texas Southwestern Medical Center, Dallas
  • Renovatio Clinical, Houston
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 22 Sep 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Urology Austin, Lakeway
  • Urology San Antonio, San Antonio
  • Woodlands Cancer Institute American Oncology Partners, The Woodlands
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Lelaki · Dikemas kini 22 Sep 2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, Austin
  • Research Site, Austin
  • Research Site, Houston
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 18 Sep 2026 · NCT06952803

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

  • MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 18 Sep 2026 · NCT06085729

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Lelaki · Dikemas kini 17 Sep 2026 · NCT05011383

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • Parkland Health & Hospital System ( Site 0069), Dallas
  • UT Southwestern Medical Center ( Site 0039), Dallas
  • University of Texas-MD Anderson Cancer Center ( Site 0055), Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 17 Sep 2026 · NCT06925737

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  • University of Texas MD Anderson Cancer Center, Houston
  • Next Oncology - Dallas, Irving
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 15 Sep 2026 · NCT07493512

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  • Urology Partners of North Texas (UPNT), Arlington
Mengambil peserta
Umur 18 ke atas · Lelaki · Dikemas kini 14 Sep 2026 · NCT06511141

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • Urology Austin, PLLC - Research Department, Austin
  • Urology Clinics of North Texas, Dallas
  • University of Texas Southwestern Medical Center, Dallas
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 11 Sep 2026 · NCT06056830

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • MD Anderson in The Woodlands, Conroe
  • Brooke Army Medical Center, Fort Sam Houston
  • UT MD Anderson Cancer Center, Houston
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 10 Sep 2026 · NCT05946213

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

  • Investigational Site Number: 401, Houston
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 10 Sep 2026 · NCT05997615

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

  • UT MD Anderson, Houston
  • NEXT Oncology, San Antonio
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06440005

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

  • SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 8 Sep 2026 · NCT05800665

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • SCRI at Mary Crowley, Dallas
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 3 Sep 2026 · NCT07545811

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  • Urology Clinics Of North Texas, Dallas
  • Urology Partners of North Texas (UPNT), Fort Worth
  • Houston Metro Urology (HMU), Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 3 Sep 2026 · NCT07723248

Prostate Active Surveillance Study

  • University of Texas Health Science Center, San Antonio, San Antonio
Mengambil pesertaKajian pemerhatian
Umur 21 ke atas · Lelaki · Dikemas kini 2 Sep 2026 · NCT00756665

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

  • University of Texas Southwestern Medical Center, Dallas
Mengambil pesertaFasa 2
Umur 18 ke atas · Lelaki · Dikemas kini 31 Ogo 2026 · NCT05726292

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • START San Antonio, San Antonio
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06582017

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.